Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative enfortumab vedotin + pembrolizumab versus neoadjuvant gemcitabine + cisplatin in cisplatin-eligible muscle-invasive bladder cancer
CTR20213351Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, enfortumab vedotin, gemcitabine, cisplatin in muscle-invasive bladder cancer (MIBC), transitional cell carcinoma (TCC), sponsored by Merck & Co.. Started Jul 2022; status: active.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20213351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213351.